Table 2.
Clinical trials approved for the use of polyphenols for COVID-19.
| Compound(s) | Intervention(s) | Title of the Study | Recruitment Status and Source |
|---|---|---|---|
| Cannabidiol | Sublingual oil drops: 3 times a day Phase 1 |
Synthetic CBD oil droplets as therapy for mild to moderate SARS-CoV-2 infection. Assessment of efficacy and safety |
Treatment: not yet recruiting ClinicalTrials.gov: NCT04686539 |
| Curcumin | 500 mg curcumin plus 5 mg piperine twice a daily for 2 weeks |
Effects of curcumin–piperine co-supplementation on disease duration, severity, and clinical signs, and inflammatory factors in patients with COVID-19: a randomized, double blind, placebo-controlled clinical trial study | Treatment: completed https://www.irct.ir/trial/47529: IRCT20121216011763N46 |
| Curcumin | Sinacurcumin® soft gel: 40 mg; 4 soft gels daily for 2 weeks |
Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized COVID-19 patients: an open-label nonrandomized clinical trial |
Treatment: completed https://www.irct.ir/trial/47529: IRCT20200408046990N1 |
| Epigallocatechin-3-gallate | Previfenon: 250 mg Phase 2/3 |
A multicenter, double-blind, randomized, placebo-controlled clinical trial to protect health workers against COVID-19 by using Previfenon as chemoprophylaxis during a SARS-CoV-2 outbreak. The HERD study | Prevention: not yet recruiting ClinicalTrials.gov: NCT04446065 |
| Resveratrol | Phase 2 | Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol, a plant polyphenol, for the outpatient treatment of mild COVID-19 | Treatment: terminated. ClinicalTrials.gov: NCT04400890 |
| Quercetin | 400 mg/daily Phase 3 |
A prospective, randomized, open-labeled, controlled trial to study the adjuvant benefits of quercetin phytosome in patients with diagnosis of COVID-19 | Treatment: completed ClinicalTrials.gov: NCT04578158 |
| Quercetin | Prophylaxis: 500 mg/daily. Treatment: 1000 mg/daily |
The possible effect of quercetin on prophylaxis and treatment of COVID-19 | Prevention and treatment: completed ClinicalTrials.gov: NCT04377789 |
| Quercetin | 600 mg/daily for 1st week; 400 mg/daily for 2nd week Phase 3 |
Study to investigate the benefits of dietary supplement quercetin for COVID-19 | Treatment: recruiting ClinicalTrials.gov: NCT04861298 |
| Quercetin | 1 tablet twice a day Phase 1 |
Effectiveness of quercetin in the treatment of SARS-CoV2 | Treatment: not yet recruiting ClinicalTrials.gov: NCT04853199 |